Svetlov S I, Sturm E, Olson M S, Crawford J M
Program in Gastrointestinal Pathology, Yale Liver Center and Yale University Medical School, New Haven, CT, USA.
Hepatology. 1999 Jul;30(1):128-36. doi: 10.1002/hep.510300122.
Normal rat bile contains secretory platelet-activating factor acetylhydrolase (PAF-AH), the enzyme capable of hydrolyzing the inflammatory mediator platelet-activating factor (PAF), and phospholipids containing oxidized truncated fatty acids. Because lecithin:cholesterol acyltransferase (LCAT) possesses intrinsic PAF-AH-like activity, it also may represent a potential anti-inflammatory enzyme. The behavior of PAF-AH and LCAT in hepatobiliary inflammatory responses in vivo has not been characterized. We therefore investigated the biliary and plasma secretion and pharmacological characteristics of these enzymes in rats subjected to intraportal bacterial endotoxin exposure (lipopolysaccharide [LPS], Escherichia coli, 055:B5). Portal vein LPS infusion (1 mg/kg, bolus) resulted in a maximal 4- to 5-fold increase in bile PAF-AH-specific activity with a gradual decline to baseline by 18 hours. Biliary PAF-AH hydrolyzed also the truncated sn-2-succinoyl and sn-2-glutaroyl analogs of PAF, indicating a broader activity of PAF-AH in bile toward byproducts of glycerophospholipid peroxidation. Plasma PAF-AH activity was not altered 5 hours after LPS injection compared with saline injection, but it was significantly elevated 18 hours after endotoxin exposure. The levels of LCAT in bile were low and declined to nearly undetectable values by 5 hours after cannulation in both control and LPS-exposed rats. Plasma LCAT activity was significantly increased after 5 hours and decreased 18 hours after LPS injection. In summary, hepatic exposure to endotoxin results in a rapid increase in biliary secretion of PAF-AH followed by elevation of LCAT and PAF-AH levels in plasma. We propose that biliary secretion of PAF-AH may be involved in the hepatic response to endotoxic insult by counteracting potential inflammatory damage in the biliary tree and gastrointestinal tract, whereas plasma increases in LCAT and PAF-AH may promote elimination of excess PAF and oxidized phospholipids in the circulation.
正常大鼠胆汁中含有分泌型血小板活化因子乙酰水解酶(PAF-AH),该酶能够水解炎症介质血小板活化因子(PAF),以及含有氧化截短脂肪酸的磷脂。由于卵磷脂胆固醇酰基转移酶(LCAT)具有内在的PAF-AH样活性,它也可能是一种潜在的抗炎酶。PAF-AH和LCAT在体内肝胆炎症反应中的行为尚未得到表征。因此,我们研究了这些酶在经门静脉内注射细菌内毒素(脂多糖[LPS],大肠杆菌,055:B5)的大鼠中的胆汁和血浆分泌及药理学特性。门静脉内注射LPS(1mg/kg,推注)导致胆汁PAF-AH比活性最大增加4至5倍,并在18小时时逐渐降至基线水平。胆汁中的PAF-AH还能水解PAF的截短sn-2-琥珀酰和sn-2-戊二酰类似物,表明胆汁中的PAF-AH对甘油磷脂过氧化副产物具有更广泛的活性。与注射生理盐水相比,LPS注射5小时后血浆PAF-AH活性未改变,但在内毒素暴露18小时后显著升高。在对照大鼠和LPS暴露大鼠中,插管后5小时胆汁中LCAT水平较低,并降至几乎无法检测的值。LPS注射后5小时血浆LCAT活性显著增加,18小时后降低。总之,肝脏暴露于内毒素会导致胆汁中PAF-AH分泌迅速增加,随后血浆中LCAT和PAF-AH水平升高。我们认为,胆汁中PAF-AH的分泌可能通过抵消胆管树和胃肠道中的潜在炎症损伤而参与肝脏对内毒素损伤的反应,而血浆中LCAT和PAF-AH的增加可能促进循环中过量PAF和氧化磷脂的清除。